2025-11910Notice

Merck Sharp Dohme Gains FTZ Okay for New Jersey Pharma Research

Published Date: 6/27/2025

Notice

Summary

Merck, Sharp & Dohme LLC got the green light to make pharmaceutical products for research and development at their Rahway, New Jersey facility inside Foreign-Trade Zone 49. This means they can produce these products with special trade benefits, helping them save money and speed up their work. The approval was finalized on June 20, 2025, with no extra reviews needed.

No Economic Impacts Identified for this Document

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Effective Date
Published Date
6/20/2025
6/27/2025

Department and Agencies

Department
Independent Agency
Agency
Commerce Department
Foreign-Trade Zones Board
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register